Rapid Plasma Reagin Test Market Updates

Global Rapid Plasma Reagin Test Market size was valued at USD 1.89 Billion in 2023 and is poised to grow from USD 2.08 Billion in 2024 to USD 4.18 Billion by 2032, growing at a CAGR of 9.1% during the forecast period (2025-2032).

Rapid plasma reagin test providers should focus on raising more awareness regarding syphilis and STI testing to boost their business scope. Investing in the R&D of novel portable and rapid tests is also a prominent opportunity for companies as per this global rapid plasma reagin test market analysis. 'Quotient Limited (Switzerland)', 'CareDx Inc. (U.S.)', 'Agena Bioscience, Inc. (Mesa Laboratories, Inc.) (U.S.)', 'DIAGAST (U.S.)', 'Illumina, Inc. (U.S.)', 'Grifols, S.A. (Spain)', 'Immucor, Inc. (U.S.)', 'Bio-Rad Laboratories, Inc. (U.S.)', 'Thermo Fisher Scientific Inc. (U.S.)', 'Merck KGaA (Germany)', 'QIAGEN (Netherlands)', 'Beckman Coulter, Inc. (Danaher) (U.S.)', 'QuidelOrtho Corporation (U.S.)'

Increasing incidence of chronic diseases coupled with high health and wellness awareness has led to robust increase in demand for preventive healthcare. Early detection of syphilis through routine screening helps prevent complications and curtails the spread of the infection. Healthcare providers are integrating RPR testing into standard preventive care protocols, especially for high-risk groups. This proactive approach aligns with broader public health goals of reducing STI prevalence and promotes regular screening.

Integration of RPR Testing with Multiplex Diagnostics: The integration of RPR tests into multiplex diagnostic platforms is a growing trend that enhances efficiency in STI screening. Multiplex tests simultaneously detect multiple infections like HIV, syphilis, and hepatitis from a single sample. This reduces testing time, costs, and logistical complexity, especially in resource-limited settings. This rapid plasma reagin test market trend supports wider adoption of RPR by embedding it into comprehensive testing strategies, offering a holistic approach to STI management and improving overall diagnostic coverage.

Why is Adoption of Rapid Plasma Reagin Test High in North America?